BLSM — BlossomHill Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1839970 ·
Last close
$15.13
Market Cap
$480.91M
52W High
$27.99
52W Low
$11.02
ADV30
173,789
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -24,670,000 | -23,758,000 | 124,131,000 | 95,376,000 | 298,911,000 |
| Mar 2026 | 0 | — | -22,107,000 | -21,008,000 | 143,410,000 | 116,003,000 | 295,530,000 |
| Jun 2025 | 0 | — | -14,103,000 | -13,244,000 | — | — | — |
| Mar 2025 | 0 | — | -11,454,000 | -10,478,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-64,295,000
Investing CF
$-1,010,000
Financing CF
$2,966,000
CapEx
$-1,010,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.92
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-179,795,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-72,334,000
Pretax Income TTM
$-68,488,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -64,024,000 | -60,555,000 | 162,968,000 | 294,696,000 | -131,728,000 | -46,925,000 |
| Dec 2024 | 0 | -36,401,000 | -30,695,000 | 106,775,000 | 179,658,000 | -72,883,000 | -31,416,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$124,131,000
Forward EPS
$-3.95
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMMP | IMMUTEP Ltd | $480.43M | $3.26 | — |
| MNPR | Monopar Therapeutics | $481.56M | $71.06 | — |
| NGNE | Neurogene Inc. | $478.19M | $23.10 | — |
| AMRN | AMARIN CORP PLC\UK | $473.82M | $11.27 | — |
| GYRE | GYRE THERAPEUTICS, INC. | $488.23M | $4.56 | — |
News headlines (Yahoo Finance, 1h cache)
BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-12 21:01 · Yahoo
BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC
2026-11-09 12:00 · Yahoo
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting
2026-11-04 12:00 · Yahoo
BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference
2026-11-03 12:00 · Yahoo
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
2026-10-22 11:00 · Yahoo
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
2026-09-28 11:00 · Yahoo
BlossomHill Therapeutics Shares Rise 4.4% After BH-30643 Trial Update
2026-09-15 14:13 · Yahoo
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
2026-09-03 11:00 · Yahoo
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
2026-09-01 11:00 · Yahoo
Insiders Are Betting Big on These 3 Healthcare Stocks
2026-08-31 17:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.